A Phase 3 interventional study of Herceptin and Herceptin in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 203 sites in 33 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-04-27.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
How we know · 4 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.
Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 3rd largest by enrollment of the 366 interventional ones that give a count, is one of 13 that started in 2001, is one of 60 in phase 3, and was the 29th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
SWOG Cancer Research Network · Sites in United States
Ages 18+
Duke University · Sites in United States
Ages 18+ · Women only
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–90
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–70 · Women only
Institut Curie · Sites in France
Ages 18+
By country, each count listing its studies:
Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, trastuzumab is the treatment under test here. Read study by study →
374 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 51 · Phase 2 270 · Phase 3 61 · Phase 4 7
First in 1998; this study’s year is marked. 13 started in 2001.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5,099 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 61 across the 366 interventional studies. Of the 235 that completed or were terminated, 128 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
73 of 374 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 88 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
229 studies in Breast Neoplasms by Hoffmann-La Roche: 16 open now, 27 under way, 13 of them phase 3. Of 194 finished, 120 (62%) have results posted.
Among the 229 studies in Breast Neoplasms by Hoffmann-La Roche, this one has the largest enrollment of the 170 interventional ones that give a count, is one of 4 that started in 2001, is one of 61 in phase 3, and was the 4th registered.
Hoffmann-La Roche’s Breast Neoplasms studies by the year they started, since 1998.
22 of the studies testing trastuzumab in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06035679Youzhi ZhuPyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer | 2026-11-30 |
| NCT05891561Shanghai Jiao Tong University School of MedicineShort-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer | 2026-12 |
| NCT04886531Ruth O'ReganTrial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers | 2026-12-22 |
| NCT07095023Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNeoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer | 2026-12-30 |
| NCT07635342Hebei Medical University Fourth HospitalPyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer | 2026-12-31 |
Add all 22 to your calendar (.ics) → With an account.
Among the 374 studies testing trastuzumab in Breast Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 229 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to evaluate Herceptin treatment for 1 year and 2 years (versus observation/no Herceptin) in women with HER2-overexpressing primary breast cancer who have completed (neo-)adjuvant systemic chemotherapy, definitive surgery, and radiotherapy, if applicable. Efficacy and safety will be assessed for 10 years from randomization for each participant. All participants will continue to be followed for survival until 10 years after enrollment of the last participant.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who have completed definitive surgery and systemic adjuvant chemotherapy will be observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin will be provided.
Participants who have completed definitive surgery and systemic adjuvant chemotherapy will receive Herceptin for 1 year or until disease recurrence, whichever occurs first. Participants will be observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.
Drug: Herceptin
Participants who have completed definitive surgery and systemic adjuvant chemotherapy will receive Herceptin for 2 years or until disease recurrence, whichever occurs first. Participants will be observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.
Drug: Herceptin
Herceptin will be given as a loading dose of 8 milligrams per kilogram (mg/kg) via intravenous (IV) infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks.
Also known as: Trastuzumab
Herceptin will be given as a loading dose of 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks.
Also known as: Trastuzumab
Percentage of Participants With Disease-Free Survival (DFS) Events in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up
DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants with at least one DFS event was reported. The analysis of the Herceptin 1-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed by the Sponsor in 2006 following database cleaning. The analysis of the Herceptin 2-Year Arm against the Observation Arm was performed for an Independent Data Monitoring Committee (IDMC) in 2005 at a time the Sponsor was blinded. Therefore, these data are reported under a separate Outcome Measure.
Time frame: From Baseline until time of event (median of 1 year)
Percentage of Participants With DFS Events in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up
DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants with at least one DFS event was reported. The analysis of the Herceptin 2-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed for an IDMC in 2005 at a time the Sponsor was blinded. The analysis of the Herceptin 1-Year Arm against the Observation Arm was performed by the Sponsor in 2006 following database cleaning. Therefore, these data are reported under a separate Outcome Measure.
Time frame: From Baseline until time of event (median of 1 year)
DFS Rate According to Kaplan-Meier Analysis in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up
DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95 percent (%) confidence interval (CI) were estimated by Kaplan-Meier analysis based on available data at the time of the 1-year median follow-up analysis. The analysis of the Herceptin 1-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed by the Sponsor in 2006 following database cleaning. The analysis of the Herceptin 2-Year Arm against the Observation Arm was performed for an IDMC in 2005 at a time the Sponsor was blinded. Therefore, these data are reported under a separate Outcome Measure.
Time frame: Year 2
DFS Rate According to Kaplan-Meier Analysis in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up
DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 1-year median follow-up analysis. The analysis of the Herceptin 2-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed for an IDMC in 2005 at a time the Sponsor was blinded. The analysis of the Herceptin 1-Year Arm against the Observation Arm was performed by the Sponsor in 2006 following database cleaning. Therefore, these data are reported under a separate Outcome Measure.
Time frame: Year 2
Percentage of Participants With DFS Events Compared to Observation: 8-Year Median Follow-Up
DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants with at least one DFS event was reported.
Time frame: From Baseline until time of event (median of 8 years)
DFS Rate at Year 3 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up
DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.
Time frame: Year 3
DFS Rate at Year 5 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up
DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.
Time frame: Year 5
DFS Rate at Year 7 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up
DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.
Time frame: Year 7
DFS Rate at Year 8 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up
DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.
Time frame: Year 8
Percentage of Participants With DFS Events Compared to Observation: 10-Year Maximum Follow-Up
DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants with at least one DFS event was reported.
Time frame: From Baseline until time of event (maximum of 10 years)
DFS Rate at Year 3 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up
DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.
Time frame: Year 3
DFS Rate at Year 5 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up
DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.
Time frame: Year 5
DFS Rate at Year 7 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up
DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.
Time frame: Year 7
DFS Rate at Year 8 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up
DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.
Time frame: Year 8
DFS Rate at Year 9 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up
DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.
Time frame: Year 9
DFS Rate at Year 10 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up
DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.
Time frame: Year 10
Percentage of Participants With DFS Events in 1-Year Versus 2-Year Herceptin: 10-Year Maximum Follow-Up
DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants with at least one DFS event was reported.
Time frame: From Baseline until time of event (maximum of 10 years)
DFS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 10-Year Maximum Follow-Up
DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.
Time frame: Years 3, 5, 7, 8, 9, 10
Percentage of Participants With Overall Survival (OS) Events in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up
OS events referred to death from any cause. The percentage of participants who died was reported. The analysis of the Herceptin 1-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed by the Sponsor in 2006 following database cleaning. The analysis of the Herceptin 2-Year Arm against the Observation Arm was performed for an IDMC in 2005 at a time the Sponsor was blinded. Therefore, these data are reported under a separate Outcome Measure.
Time frame: From Baseline until time of event (median of 1 year)
Percentage of Participants With OS Events in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up
OS events referred to death from any cause. The percentage of participants who died was reported. The analysis of the Herceptin 2-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed for an IDMC in 2005 at a time the Sponsor was blinded. The analysis of the Herceptin 1-Year Arm against the Observation Arm was performed by the Sponsor in 2006 following database cleaning. Therefore, these data are reported under a separate Outcome Measure.
Time frame: From Baseline until time of event (median of 1 year)
OS Rate According to Kaplan-Meier Analysis in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up
OS events referred to death from any cause. The percentage of participants alive (i.e., the OS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 1-year median follow-up analysis. The analysis of the Herceptin 1-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed by the Sponsor in 2006 following database cleaning. The analysis of the Herceptin 2-Year Arm against the Observation Arm was performed for an IDMC in 2005 at a time the Sponsor was blinded. Therefore, these data are reported under a separate Outcome Measure.
Time frame: Year 2
OS Rate According to Kaplan-Meier Analysis in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up
OS events referred to death from any cause. The percentage of participants alive (i.e., the OS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 1-year median follow-up analysis. The analysis of the Herceptin 2-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed for an IDMC in 2005 at a time the Sponsor was blinded. The analysis of the Herceptin 1-Year Arm against the Observation Arm was performed by the Sponsor in 2006 following database cleaning. Therefore, these data are reported under a separate Outcome Measure.
Time frame: Year 2
Percentage of Participants With OS Events Compared to Observation: 8-Year Median Follow-Up
OS events referred to death from any cause. The percentage of participants who died was reported.
Time frame: From Baseline until time of event (median of 8 years)
OS Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up
OS events referred to death from any cause. The percentage of participants alive (i.e., the OS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.
Time frame: Years 3, 5, 7, 8
Percentage of Participants With OS Events Compared to Observation: 11-Year Median Follow-Up
OS events referred to death from any cause. The percentage of participants who died was reported.
Time frame: From Baseline until time of event (median of 11 years)
OS Rate According to Kaplan-Meier Analysis Compared to Observation: 11-Year Median Follow-Up
OS events referred to death from any cause. The percentage of participants alive (i.e., the OS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with an 11-year median follow-up for OS events.
Time frame: Years 3, 5, 7, 9, 10, 11, 12
Percentage of Participants With OS Events in 1-Year Versus 2-Year Herceptin: 11-Year Median Follow-Up
OS events referred to death from any cause. The percentage of participants who died was reported.
Time frame: From Baseline until time of event (median of 11 years)
OS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 11-Year Median Follow-Up
OS events referred to death from any cause. The percentage of participants alive (i.e., the OS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with an 11-year median follow-up for OS events.
Time frame: Years 3, 5, 7, 9, 10, 11, 12
Percentage of Participants With Recurrence-Free Survival (RFS) Events Compared to Observation: 8-Year Median Follow-Up
RFS events included local, regional, or distant tumor recurrence. The percentage of participants with at least one RFS event was reported.
Time frame: From Baseline until time of event (median of 8 years)
RFS Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up
RFS events included local, regional, or distant tumor recurrence. The percentage of participants free of RFS events (i.e., the RFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.
Time frame: Years 3, 5, 7, 8
Percentage of Participants With RFS Events in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up
RFS events included local, regional, or distant tumor recurrence. The percentage of participants with at least one RFS event was reported.
Time frame: From Baseline until time of event (median of 8 years)
RFS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up
RFS events included local, regional, or distant tumor recurrence. The percentage of participants free of RFS events (i.e., the RFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.
Time frame: Years 3, 5, 7, 8
Percentage of Participants With Distant Disease-Free Survival (DDFS) Events Compared to Observation: 8-Year Median Follow-Up
DDFS events included distant tumor recurrence, second primary cancer, or contralateral breast cancer. The percentage of participants with at least one DDFS event was reported.
Time frame: From Baseline until time of event (median of 8 years)
DDFS Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up
DDFS events included distant tumor recurrence, second primary cancer, or contralateral breast cancer. The percentage of participants free of DDFS events (i.e., the DDFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.
Time frame: Years 3, 5, 7, 8
Percentage of Participants With DDFS Events in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up
DDFS events included distant tumor recurrence, second primary cancer, or contralateral breast cancer. The percentage of participants with at least one DDFS event was reported.
Time frame: From Baseline until time of event (median of 8 years)
DDFS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up
DDFS events included distant tumor recurrence, second primary cancer, or contralateral breast cancer. The percentage of participants free of DDFS events (i.e., the DDFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.
Time frame: Years 3, 5, 7, 8
Percentage of Participants With Tumor Recurrence (TR) Compared to Observation: 8-Year Median Follow-Up
The percentage of participants with TR of the present breast cancer was reported. TR included local, regional, or distant tumor ignoring contralateral breast cancer and second non-breast malignancy.
Time frame: From Baseline until time of event (median of 8 years)
TR-Free Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up
The percentage of participants without TR of the present breast cancer (i.e., the TR-free rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis. TR included local, regional, or distant tumor ignoring contralateral breast cancer and second non-breast malignancy.
Time frame: Years 3, 5, 7, 8
Percentage of Participants With TR in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up
The percentage of participants with TR of the present breast cancer was reported. TR included local, regional, or distant tumor ignoring contralateral breast cancer and second non-breast malignancy.
Time frame: From Baseline until time of event (median of 8 years)
TR-Free Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up
The percentage of participants without TR of the present breast cancer (i.e., the TR-free rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis. TR included local, regional, or distant tumor ignoring contralateral breast cancer and second non-breast malignancy.
Time frame: Years 3, 5, 7, 8
Percentage of Participants With Distant Tumor Recurrence (DTR) Compared to Observation: 8-Year Median Follow-Up
The percentage of participants with DTR was reported. DTR included distant tumors ignoring local and regional recurrences, contralateral breast cancer, and second non-breast malignancy.
Time frame: From Baseline until time of event (median of 8 years)
DTR-Free Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up
The percentage of participants without DTR (i.e., the DTR-free rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis. DTR included distant tumors ignoring local and regional recurrences, contralateral breast cancer, and second non-breast malignancy.
Time frame: Years 3, 5, 7, 8
Percentage of Participants With DTR in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up
The percentage of participants with DTR was reported. DTR included distant tumors ignoring local and regional recurrences, contralateral breast cancer, and second non-breast malignancy.
Time frame: From Baseline until time of event (median of 8 years)
DTR-Free Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up
The percentage of participants without DTR (i.e., the DTR-free rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis. DTR included distant tumors ignoring local and regional recurrences, contralateral breast cancer, and second non-breast malignancy.
Time frame: Years 3, 5, 7, 8
Percentage of Participants With Restricted Disease-Free Survival (RDFS) Events in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up
RDFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer, or death from any cause. The percentage of participants with at least one RDFS event was reported.
Time frame: From Baseline until time of event (median of 8 years)
RDFS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up
RDFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer, or death from any cause. The percentage of participants free of RDFS events (i.e., the RDFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.
Time frame: Years 3, 5, 7, 8
Percentage of Participants With Primary Cardiac Endpoint Events Compared to Observation: 10-Year Maximum Follow-Up
Primary cardiac endpoint events included the occurrence of any of the following between randomization and new therapy for recurrent disease: symptomatic New York Heart Association (NYHA) Class III or IV congestive heart failure (CHF) confirmed by a cardiologist with a drop in left ventricular ejection fraction (LVEF) at least 10 percentage points from Baseline and to a value less than (\<) 50%, and documentation of definite or probable cardiac death. Definite cardiac death included CHF, myocardial infarction, or primary arrhythmia. Probable cardiac death included unexpected sudden death within 24 hours of a cardiac event (syncope, cardiac arrest, chest pain, infarction, arrhythmia) without documented etiology. The percentage of participants with at least one primary cardiac endpoint event was reported. The 95% CI was calculated by the Pearson-Clopper method for a one-sample binomial.
Time frame: From Baseline until time of event (maximum up to 10 years)
Percentage of Participants With Secondary Cardiac Endpoint Events Compared to Observation: 10-Year Maximum Follow-Up
Secondary cardiac endpoint events included NYHA Class I or II CHF with a drop in LVEF measured by multiple-gated acquisition or electrocardiogram, unless the subsequent assessment of LVEF indicated a return to levels that did not meet the definition of a significant LVEF drop. A significant LVEF drop was defined as an absolute reduction of at least 10 percentage points from Baseline and to a value \<50%. The percentage of participants with at least one secondary cardiac endpoint event was reported, excluding those with both a primary and secondary cardiac endpoint event. The 95% CI was calculated by the Pearson-Clopper method for a one-sample binomial.
Time frame: From Baseline until time of event (maximum up to 10 years)
| Milestone | Observation Arm | Herceptin 1-Year Arm | Herceptin 2-Year Arm |
|---|---|---|---|
| Started | 1697 | 1702 | 1700 |
| Crossover to adjuvant herceptin | 888 | 0 | 0 |
| Completed | 834 | 994 | 974 |
| Not completed | 863 | 708 | 726 |
| Withdrew: Adverse event/intercurrent illness | 2 | 2 | 7 |
| Withdrew: Death | 22 | 24 | 17 |
| Withdrew: Insufficient therapeutic response | 542 | 437 | 445 |
| Withdrew: Violation of selection criteria at entry | 3 | 6 | 6 |
| Withdrew: Other protocol violation | 2 | 0 | 1 |
| Withdrew: Refused/did not cooperate/withdrew | 142 | 93 | 84 |
| Withdrew: Failure to return | 57 | 62 | 61 |
| Withdrew: Other | 93 | 84 | 105 |
DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants with at least one DFS event was reported. The analysis of the Herceptin 1-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed by the Sponsor in 2006 following database cleaning. The analysis of the Herceptin 2-Year Arm against the Observation Arm was performed for an Independent Data Monitoring Committee (IDMC) in 2005 at a time the Sponsor was blinded. Therefore, these data are reported under a separate Outcome Measure.
| percentage of participants | Observation Arm | Herceptin 1-Year Arm |
|---|---|---|
| Percentage of Participants With Disease-Free Survival (DFS) Events in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up | 12.9 | 7.5 |
DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants with at least one DFS event was reported. The analysis of the Herceptin 2-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed for an IDMC in 2005 at a time the Sponsor was blinded. The analysis of the Herceptin 1-Year Arm against the Observation Arm was performed by the Sponsor in 2006 following database cleaning. Therefore, these data are reported under a separate Outcome Measure.
| percentage of participants | Observation Arm | Herceptin 2-Year Arm |
|---|---|---|
| Percentage of Participants With DFS Events in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up | 13.0 | 7.6 |
DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95 percent (%) confidence interval (CI) were estimated by Kaplan-Meier analysis based on available data at the time of the 1-year median follow-up analysis. The analysis of the Herceptin 1-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed by the Sponsor in 2006 following database cleaning. The analysis of the Herceptin 2-Year Arm against the Observation Arm was performed for an IDMC in 2005 at a time the Sponsor was blinded. Therefore, these data are reported under a separate Outcome Measure.
| percentage of participants | Observation Arm | Herceptin 1-Year Arm |
|---|---|---|
| DFS Rate According to Kaplan-Meier Analysis in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up | 78.18 (75 to 81) | 85.80 (83 to 89) |
DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 1-year median follow-up analysis. The analysis of the Herceptin 2-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed for an IDMC in 2005 at a time the Sponsor was blinded. The analysis of the Herceptin 1-Year Arm against the Observation Arm was performed by the Sponsor in 2006 following database cleaning. Therefore, these data are reported under a separate Outcome Measure.
| percentage of participants | Observation Arm | Herceptin 2-Year Arm |
|---|---|---|
| DFS Rate According to Kaplan-Meier Analysis in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up | 73.60 (70 to 77) | 87.50 (85 to 90) |
DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants with at least one DFS event was reported.
| percentage of participants | Observation Arm | Herceptin 1-Year Arm | Herceptin 2-Year Arm |
|---|---|---|---|
| Percentage of Participants With DFS Events Compared to Observation: 8-Year Median Follow-Up | 33.6 | 27.7 | 27.8 |
DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.
| percentage of participants | Observation Arm | Herceptin 1-Year Arm | Herceptin 2-Year Arm |
|---|---|---|---|
| DFS Rate at Year 3 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up | 75.2 (73.1 to 77.3) | 81.3 (79.4 to 83.2) | 83.5 (81.7 to 85.3) |
DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.
| percentage of participants | Observation Arm | Herceptin 1-Year Arm | Herceptin 2-Year Arm |
|---|---|---|---|
| DFS Rate at Year 5 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up | 70.0 (67.8 to 72.3) | 75.9 (73.8 to 78.0) | 76.5 (74.4 to 78.5) |
DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.
| percentage of participants | Observation Arm | Herceptin 1-Year Arm | Herceptin 2-Year Arm |
|---|---|---|---|
| DFS Rate at Year 7 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up | 66.0 (63.6 to 68.3) | 72.4 (70.2 to 74.6) | 72.5 (70.4 to 74.7) |
DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.
| percentage of participants | Observation Arm | Herceptin 1-Year Arm | Herceptin 2-Year Arm |
|---|---|---|---|
| DFS Rate at Year 8 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up | 64.8 (62.4 to 67.2) | 71.2 (69.0 to 73.4) | 71.0 (68.7 to 73.2) |
DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants with at least one DFS event was reported.
| percentage of participants | Observation Arm | Herceptin 1-Year Arm | Herceptin 2-Year Arm |
|---|---|---|---|
| Percentage of Participants With DFS Events Compared to Observation: 10-Year Maximum Follow-Up | 35.8 | 29.7 | 30.5 |
DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.
| percentage of participants | Observation Arm | Herceptin 1-Year Arm | Herceptin 2-Year Arm |
|---|---|---|---|
| DFS Rate at Year 3 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up | 75.2 (73.1 to 77.3) | 81.3 (79.4 to 83.2) | 83.4 (81.6 to 85.2) |
DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.
| percentage of participants | Observation Arm | Herceptin 1-Year Arm | Herceptin 2-Year Arm |
|---|---|---|---|
| DFS Rate at Year 5 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up | 70.0 (67.8 to 72.2) | 75.9 (73.8 to 78.0) | 76.4 (74.4 to 78.5) |
DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.
| percentage of participants | Observation Arm | Herceptin 1-Year Arm | Herceptin 2-Year Arm |
|---|---|---|---|
| DFS Rate at Year 7 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up | 65.8 (63.5 to 68.2) | 72.4 (70.2 to 74.5) | 72.5 (70.3 to 74.7) |
DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.
| percentage of participants | Observation Arm | Herceptin 1-Year Arm | Herceptin 2-Year Arm |
|---|---|---|---|
| DFS Rate at Year 8 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up | 64.7 (62.3 to 67.0) | 71.2 (69.0 to 73.4) | 70.7 (68.5 to 72.9) |
DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.
| percentage of participants | Observation Arm | Herceptin 1-Year Arm | Herceptin 2-Year Arm |
|---|---|---|---|
| DFS Rate at Year 9 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up | 63.5 (61.2 to 65.9) | 70.3 (68.1 to 72.6) | 69.2 (67.0 to 71.5) |
DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.
| percentage of participants | Observation Arm | Herceptin 1-Year Arm | Herceptin 2-Year Arm |
|---|---|---|---|
| DFS Rate at Year 10 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up | 62.5 (60.1 to 64.8) | 69.3 (67.0 to 71.5) | 68.5 (66.2 to 70.7) |
DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants with at least one DFS event was reported.
| percentage of participants | Herceptin 1-Year Arm | Herceptin 2-Year Arm |
|---|---|---|
| Percentage of Participants With DFS Events in 1-Year Versus 2-Year Herceptin: 10-Year Maximum Follow-Up | 25.8 | 26.6 |
DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.
| percentage of participants | Herceptin 1-Year Arm | Herceptin 2-Year Arm |
|---|---|---|
| Year 3 | 86.7 (85.0 to 88.4) | 89.0 (87.4 to 90.6) |
| Year 5 | 81.0 (79.0 to 82.9) | 81.6 (79.6 to 83.5) |
| Year 7 | 77.2 (75.1 to 79.3) | 77.4 (75.3 to 79.5) |
| Year 8 | 75.9 (73.8 to 78.1) | 75.5 (73.3 to 77.7) |
| Year 9 | 75.0 (72.8 to 77.2) | 73.9 (71.7 to 76.1) |
| Year 10 | 73.9 (71.7 to 76.1) | 73.1 (70.8 to 75.3) |
OS events referred to death from any cause. The percentage of participants who died was reported. The analysis of the Herceptin 1-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed by the Sponsor in 2006 following database cleaning. The analysis of the Herceptin 2-Year Arm against the Observation Arm was performed for an IDMC in 2005 at a time the Sponsor was blinded. Therefore, these data are reported under a separate Outcome Measure.
| percentage of participants | Observation Arm | Herceptin 1-Year Arm |
|---|---|---|
| Percentage of Participants With Overall Survival (OS) Events in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up | 2.4 | 1.8 |
OS events referred to death from any cause. The percentage of participants who died was reported. The analysis of the Herceptin 2-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed for an IDMC in 2005 at a time the Sponsor was blinded. The analysis of the Herceptin 1-Year Arm against the Observation Arm was performed by the Sponsor in 2006 following database cleaning. Therefore, these data are reported under a separate Outcome Measure.
| percentage of participants | Observation Arm | Herceptin 2-Year Arm |
|---|---|---|
| Percentage of Participants With OS Events in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up | 2.2 | 1.4 |
OS events referred to death from any cause. The percentage of participants alive (i.e., the OS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 1-year median follow-up analysis. The analysis of the Herceptin 1-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed by the Sponsor in 2006 following database cleaning. The analysis of the Herceptin 2-Year Arm against the Observation Arm was performed for an IDMC in 2005 at a time the Sponsor was blinded. Therefore, these data are reported under a separate Outcome Measure.
| percentage of participants | Observation Arm | Herceptin 1-Year Arm |
|---|---|---|
| OS Rate According to Kaplan-Meier Analysis in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up | 94.98 (93 to 97) | 95.88 (94 to 98) |
OS events referred to death from any cause. The percentage of participants alive (i.e., the OS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 1-year median follow-up analysis. The analysis of the Herceptin 2-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed for an IDMC in 2005 at a time the Sponsor was blinded. The analysis of the Herceptin 1-Year Arm against the Observation Arm was performed by the Sponsor in 2006 following database cleaning. Therefore, these data are reported under a separate Outcome Measure.
| percentage of participants | Observation Arm | Herceptin 2-Year Arm |
|---|---|---|
| OS Rate According to Kaplan-Meier Analysis in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up | 94.39 (92 to 97) | 97.28 (96 to 98) |
OS events referred to death from any cause. The percentage of participants who died was reported.
| percentage of participants | Observation Arm | Herceptin 1-Year Arm | Herceptin 2-Year Arm |
|---|---|---|---|
| Percentage of Participants With OS Events Compared to Observation: 8-Year Median Follow-Up | 20.6 | 16.3 | 16.1 |
OS events referred to death from any cause. The percentage of participants alive (i.e., the OS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.
| percentage of participants | Observation Arm | Herceptin 1-Year Arm | Herceptin 2-Year Arm |
|---|---|---|---|
| Year 3 | 90.7 (89.3 to 92.1) | 92.7 (91.5 to 94.0) | 94.4 (93.3 to 95.6) |
| Year 5 | 84.5 (82.8 to 86.3) | 86.9 (85.2 to 88.5) | 88.7 (87.2 to 90.3) |
| Year 7 | 79.5 (77.5 to 81.5) | 83.9 (82.1 to 85.7) | 84.6 (82.9 to 86.4) |
| Year 8 | 77.4 (75.2 to 79.5) | 82.7 (80.8 to 84.6) | 82.4 (80.4 to 84.3) |
OS events referred to death from any cause. The percentage of participants who died was reported.
| percentage of participants | Observation Arm | Herceptin 1-Year Arm | Herceptin 2-Year Arm |
|---|---|---|---|
| Percentage of Participants With OS Events Compared to Observation: 11-Year Median Follow-Up | 23.9 | 18.8 | 18.4 |
OS events referred to death from any cause. The percentage of participants alive (i.e., the OS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with an 11-year median follow-up for OS events.
| percentage of participants | Observation Arm | Herceptin 1-Year Arm | Herceptin 2-Year Arm |
|---|---|---|---|
| Year 3 | 90.7 (89.3 to 92.1) | 92.7 (91.5 to 94.0) | 94.4 (93.3 to 95.6) |
| Year 5 | 84.5 (82.8 to 86.3) | 86.9 (85.2 to 88.5) | 88.7 (87.2 to 90.3) |
| Year 7 | 79.4 (77.4 to 81.4) | 83.8 (82.0 to 85.6) | 84.7 (82.9 to 86.4) |
| Year 9 | 76.5 (74.4 to 78.6) | 81.9 (80.0 to 83.8) | 81.8 (80.0 to 83.7) |
| Year 10 | 75.0 (72.9 to 77.2) | 80.7 (78.8 to 82.6) | 81.0 (79.0 to 82.9) |
| Year 11 | 73.7 (71.5 to 76.0) | 80.0 (78.1 to 82.0) | 80.3 (78.3 to 82.3) |
| Year 12 | 72.9 (70.4 to 75.3) | 79.4 (77.3 to 81.5) | 79.5 (77.4 to 81.7) |
OS events referred to death from any cause. The percentage of participants who died was reported.
| percentage of participants | Herceptin 1-Year Arm | Herceptin 2-Year Arm |
|---|---|---|
| Percentage of Participants With OS Events in 1-Year Versus 2-Year Herceptin: 11-Year Median Follow-Up | 14.7 | 14.9 |
OS events referred to death from any cause. The percentage of participants alive (i.e., the OS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with an 11-year median follow-up for OS events.
| percentage of participants | Herceptin 1-Year Arm | Herceptin 2-Year Arm |
|---|---|---|
| Year 3 | 96.5 (95.6 to 97.4) | 97.4 (96.6 to 98.2) |
| Year 5 | 91.4 (90.0 to 92.8) | 92.6 (91.2 to 93.9) |
| Year 7 | 88.6 (87.0 to 90.2) | 88.7 (87.1 to 90.3) |
| Year 9 | 86.7 (85.0 to 88.5) | 85.9 (84.2 to 87.7) |
| Year 10 | 85.4 (83.6 to 87.2) | 85.1 (83.3 to 86.9) |
| Year 11 | 84.7 (82.9 to 86.6) | 84.4 (82.5 to 86.2) |
| Year 12 | 84.1 (82.1 to 86.1) | 83.6 (81.5 to 85.6) |
RFS events included local, regional, or distant tumor recurrence. The percentage of participants with at least one RFS event was reported.
| percentage of participants | Observation Arm | Herceptin 1-Year Arm | Herceptin 2-Year Arm |
|---|---|---|---|
| Percentage of Participants With Recurrence-Free Survival (RFS) Events Compared to Observation: 8-Year Median Follow-Up | 29.8 | 23.4 | 22.6 |
RFS events included local, regional, or distant tumor recurrence. The percentage of participants free of RFS events (i.e., the RFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.
| percentage of participants | Observation Arm | Herceptin 1-Year Arm | Herceptin 2-Year Arm |
|---|---|---|---|
| Year 3 | 76.4 (74.3 to 78.4) | 82.7 (80.9 to 84.6) | 86.0 (84.3 to 87.6) |
| Year 5 | 71.9 (69.7 to 74.1) | 78.4 (76.4 to 80.4) | 79.9 (77.9 to 81.9) |
| Year 7 | 69.0 (66.7 to 71.3) | 75.7 (73.6 to 77.8) | 76.7 (74.6 to 78.8) |
| Year 8 | 68.4 (66.1 to 70.7) | 75.1 (72.9 to 77.2) | 75.8 (73.6 to 77.9) |
RFS events included local, regional, or distant tumor recurrence. The percentage of participants with at least one RFS event was reported.
| percentage of participants | Herceptin 1-Year Arm | Herceptin 2-Year Arm |
|---|---|---|
| Percentage of Participants With RFS Events in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up | 19.7 | 18.8 |
RFS events included local, regional, or distant tumor recurrence. The percentage of participants free of RFS events (i.e., the RFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.
| percentage of participants | Herceptin 1-Year Arm | Herceptin 2-Year Arm |
|---|---|---|
| Year 3 | 87.7 (86.0 to 89.3) | 90.9 (89.4 to 92.3) |
| Year 5 | 83.1 (81.2 to 85.0) | 84.5 (82.7 to 86.4) |
| Year 7 | 80.2 (78.2 to 82.3) | 81.3 (79.3 to 83.2) |
| Year 8 | 79.6 (77.5 to 81.6) | 80.3 (78.2 to 82.3) |
DDFS events included distant tumor recurrence, second primary cancer, or contralateral breast cancer. The percentage of participants with at least one DDFS event was reported.
| percentage of participants | Observation Arm | Herceptin 1-Year Arm | Herceptin 2-Year Arm |
|---|---|---|---|
| Percentage of Participants With Distant Disease-Free Survival (DDFS) Events Compared to Observation: 8-Year Median Follow-Up | 28.8 | 23.4 | 23.2 |
DDFS events included distant tumor recurrence, second primary cancer, or contralateral breast cancer. The percentage of participants free of DDFS events (i.e., the DDFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.
| percentage of participants | Observation Arm | Herceptin 1-Year Arm | Herceptin 2-Year Arm |
|---|---|---|---|
| Year 3 | 78.6 (76.6 to 80.6) | 84.4 (82.7 to 86.2) | 85.9 (84.2 to 87.6) |
| Year 5 | 74.2 (72.1 to 76.4) | 79.6 (77.6 to 81.6) | 80.2 (78.2 to 82.1) |
| Year 7 | 70.8 (68.6 to 73.1) | 76.7 (74.6 to 78.8) | 76.7 (74.6 to 78.8) |
| Year 8 | 69.6 (67.3 to 71.9) | 75.5 (73.4 to 77.6) | 75.6 (73.4 to 77.7) |
DDFS events included distant tumor recurrence, second primary cancer, or contralateral breast cancer. The percentage of participants with at least one DDFS event was reported.
| percentage of participants | Herceptin 1-Year Arm | Herceptin 2-Year Arm |
|---|---|---|
| Percentage of Participants With DDFS Events in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up | 19.5 | 19.5 |
DDFS events included distant tumor recurrence, second primary cancer, or contralateral breast cancer. The percentage of participants free of DDFS events (i.e., the DDFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.
| percentage of participants | Herceptin 1-Year Arm | Herceptin 2-Year Arm |
|---|---|---|
| Year 3 | 89.4 (87.9 to 91.0) | 90.8 (89.4 to 92.2) |
| Year 5 | 84.5 (82.7 to 86.3) | 84.7 (82.9 to 86.5) |
| Year 7 | 81.4 (79.5 to 83.4) | 81.1 (79.1 to 83.1) |
| Year 8 | 80.1 (78.1 to 82.2) | 79.9 (77.8 to 81.9) |
The percentage of participants with TR of the present breast cancer was reported. TR included local, regional, or distant tumor ignoring contralateral breast cancer and second non-breast malignancy.
| percentage of participants | Observation Arm | Herceptin 1-Year Arm | Herceptin 2-Year Arm |
|---|---|---|---|
| Percentage of Participants With Tumor Recurrence (TR) Compared to Observation: 8-Year Median Follow-Up | 29.8 | 23.4 | 22.6 |
The percentage of participants without TR of the present breast cancer (i.e., the TR-free rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis. TR included local, regional, or distant tumor ignoring contralateral breast cancer and second non-breast malignancy.
| percentage of participants | Observation Arm | Herceptin 1-Year Arm | Herceptin 2-Year Arm |
|---|---|---|---|
| Year 3 | 76.5 (74.4 to 78.5) | 82.8 (81.0 to 84.6) | 86.1 (84.4 to 87.7) |
| Year 5 | 72.1 (69.9 to 74.3) | 78.6 (76.6 to 80.6) | 80.1 (78.2 to 82.1) |
| Year 7 | 69.2 (67.0 to 71.5) | 75.9 (73.9 to 78.0) | 77.0 (75.0 to 79.1) |
| Year 8 | 68.6 (66.4 to 70.9) | 75.3 (73.2 to 77.4) | 76.2 (74.1 to 78.3) |
The percentage of participants with TR of the present breast cancer was reported. TR included local, regional, or distant tumor ignoring contralateral breast cancer and second non-breast malignancy.
| percentage of participants | Herceptin 1-Year Arm | Herceptin 2-Year Arm |
|---|---|---|
| Percentage of Participants With TR in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up | 19.7 | 18.8 |
The percentage of participants without TR of the present breast cancer (i.e., the TR-free rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis. TR included local, regional, or distant tumor ignoring contralateral breast cancer and second non-breast malignancy.
| percentage of participants | Herceptin 1-Year Arm | Herceptin 2-Year Arm |
|---|---|---|
| Year 3 | 87.7 (86.1 to 89.4) | 90.9 (89.5 to 92.4) |
| Year 5 | 83.2 (81.3 to 85.1) | 84.7 (82.9 to 86.5) |
| Year 7 | 80.4 (78.4 to 82.4) | 81.5 (79.6 to 83.5) |
| Year 8 | 79.8 (77.7 to 81.8) | 80.6 (78.6 to 82.6) |
The percentage of participants with DTR was reported. DTR included distant tumors ignoring local and regional recurrences, contralateral breast cancer, and second non-breast malignancy.
| percentage of participants | Observation Arm | Herceptin 1-Year Arm | Herceptin 2-Year Arm |
|---|---|---|---|
| Percentage of Participants With Distant Tumor Recurrence (DTR) Compared to Observation: 8-Year Median Follow-Up | 25.3 | 19.4 | 18.8 |
The percentage of participants without DTR (i.e., the DTR-free rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis. DTR included distant tumors ignoring local and regional recurrences, contralateral breast cancer, and second non-breast malignancy.
| percentage of participants | Observation Arm | Herceptin 1-Year Arm | Herceptin 2-Year Arm |
|---|---|---|---|
| Year 3 | 79.8 (77.8 to 81.7) | 85.9 (84.2 to 87.6) | 88.1 (86.5 to 89.6) |
| Year 5 | 76.5 (74.4 to 78.5) | 82.1 (80.2 to 84.0) | 83.4 (81.5 to 85.2) |
| Year 7 | 74.0 (71.8 to 76.1) | 80.1 (78.2 to 82.1) | 80.7 (78.8 to 82.6) |
| Year 8 | 73.3 (71.1 to 75.5) | 79.5 (77.5 to 81.5) | 80.3 (78.3 to 82.2) |
The percentage of participants with DTR was reported. DTR included distant tumors ignoring local and regional recurrences, contralateral breast cancer, and second non-breast malignancy.
| percentage of participants | Herceptin 1-Year Arm | Herceptin 2-Year Arm |
|---|---|---|
| Percentage of Participants With DTR in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up | 15.5 | 15.1 |
The percentage of participants without DTR (i.e., the DTR-free rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis. DTR included distant tumors ignoring local and regional recurrences, contralateral breast cancer, and second non-breast malignancy.
| percentage of participants | Herceptin 1-Year Arm | Herceptin 2-Year Arm |
|---|---|---|
| Year 3 | 90.5 (89.0 to 91.9) | 92.4 (91.1 to 93.8) |
| Year 5 | 86.7 (85.0 to 88.4) | 87.5 (85.8 to 89.2) |
| Year 7 | 84.6 (82.8 to 86.4) | 84.9 (83.1 to 86.7) |
| Year 8 | 83.9 (82.1 to 85.8) | 84.4 (82.6 to 86.3) |
RDFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer, or death from any cause. The percentage of participants with at least one RDFS event was reported.
| percentage of participants | Herceptin 1-Year Arm | Herceptin 2-Year Arm |
|---|---|---|
| Percentage of Participants With Restricted Disease-Free Survival (RDFS) Events in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up | 22.2 | 21.9 |
RDFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer, or death from any cause. The percentage of participants free of RDFS events (i.e., the RDFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.
| percentage of participants | Herceptin 1-Year Arm | Herceptin 2-Year Arm |
|---|---|---|
| Year 3 | 87.3 (85.6 to 89.0) | 89.9 (88.4 to 91.4) |
| Year 5 | 81.9 (79.9 to 83.8) | 83.0 (81.1 to 84.9) |
| Year 7 | 78.5 (76.4 to 80.6) | 78.9 (76.9 to 81.0) |
| Year 8 | 77.2 (75.1 to 79.3) | 77.7 (75.5 to 79.8) |
Primary cardiac endpoint events included the occurrence of any of the following between randomization and new therapy for recurrent disease: symptomatic New York Heart Association (NYHA) Class III or IV congestive heart failure (CHF) confirmed by a cardiologist with a drop in left ventricular ejection fraction (LVEF) at least 10 percentage points from Baseline and to a value less than (\<) 50%, and documentation of definite or probable cardiac death. Definite cardiac death included CHF, myocardial infarction, or primary arrhythmia. Probable cardiac death included unexpected sudden death within 24 hours of a cardiac event (syncope, cardiac arrest, chest pain, infarction, arrhythmia) without documented etiology. The percentage of participants with at least one primary cardiac endpoint event was reported. The 95% CI was calculated by the Pearson-Clopper method for a one-sample binomial.
| percentage of participants | Observation Arm | Herceptin 1-Year Arm | Herceptin 2-Year Arm |
|---|---|---|---|
| Percentage of Participants With Primary Cardiac Endpoint Events Compared to Observation: 10-Year Maximum Follow-Up | 0.11 (0.01 to 0.41) | 1.07 (0.64 to 1.69) | 1.02 (0.59 to 1.62) |
Secondary cardiac endpoint events included NYHA Class I or II CHF with a drop in LVEF measured by multiple-gated acquisition or electrocardiogram, unless the subsequent assessment of LVEF indicated a return to levels that did not meet the definition of a significant LVEF drop. A significant LVEF drop was defined as an absolute reduction of at least 10 percentage points from Baseline and to a value \<50%. The percentage of participants with at least one secondary cardiac endpoint event was reported, excluding those with both a primary and secondary cardiac endpoint event. The 95% CI was calculated by the Pearson-Clopper method for a one-sample binomial.
| percentage of participants | Observation Arm | Herceptin 1-Year Arm | Herceptin 2-Year Arm |
|---|---|---|---|
| Percentage of Participants With Secondary Cardiac Endpoint Events Compared to Observation: 10-Year Maximum Follow-Up | 0.86 (0.48 to 1.41) | 4.40 (3.47 to 5.49) | 7.29 (6.09 to 8.64) |
Collected over From Baseline until end of treatment (maximum up to 2 years) with the exception of cardiac/cardiovascular events, second primary malignancies, pregnancies, and Herceptin-related adverse events (maximum up to 10 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Observation Arm | — | 143/1,744 (8.2%) | 1,076/1,744 (61.7%) |
| Herceptin 1-Year Arm | — | 269/1,682 (16%) | 1,389/1,682 (82.6%) |
| Herceptin 2-Year Arm | — | 344/1,673 (20.6%) | 1,440/1,673 (86.1%) |
| Event | Observation Arm | Herceptin 1-Year Arm | Herceptin 2-Year Arm |
|---|---|---|---|
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 9/1744 | 27/1682 | 36/1673 |
| PregnancyPregnancy, puerperium and perinatal conditions | 11/1744 | 22/1682 | 29/1673 |
| Cardiac failure congestiveCardiac disorders | 1/1744 | 19/1682 | 24/1673 |
| Device related infectionInfections and infestations | 2/1744 | 9/1682 | 8/1673 |
| Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/1744 | 8/1682 | 8/1673 |
| ErysipelasInfections and infestations | 1/1744 | 8/1682 | 4/1673 |
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/1744 | 1/1682 | 7/1673 |
| Endometrial hyperplasiaReproductive system and breast disorders | 3/1744 | 4/1682 | 7/1673 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/1744 | 7/1682 | 1/1673 |
| PyrexiaGeneral disorders | 0/1744 | 3/1682 | 6/1673 |
| Event | Observation Arm | Herceptin 1-Year Arm | Herceptin 2-Year Arm |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 65/1744 | 187/1682 | 269/1673 |
| HeadacheNervous system disorders | 72/1744 | 201/1682 | 250/1673 |
| FatigueGeneral disorders | 83/1744 | 198/1682 | 246/1673 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 152/1744 | 225/1682 | 246/1673 |
| DiarrhoeaGastrointestinal disorders | 22/1744 | 155/1682 | 180/1673 |
| Hot flushVascular disorders | 130/1744 | 166/1682 | 159/1673 |
| NauseaGastrointestinal disorders | 37/1744 | 134/1682 | 157/1673 |
| CoughRespiratory, thoracic and mediastinal disorders | 62/1744 | 116/1682 | 147/1673 |
| Back painMusculoskeletal and connective tissue disorders | 106/1744 | 146/1682 | 137/1673 |
| PyrexiaGeneral disorders | 12/1744 | 116/1682 | 145/1673 |
Full Analysis Set (FAS) Population: All enrolled/randomized participants who had an available signed Informed Consent Form.
| Age, Continuous(years) | Observation Arm | Herceptin 1-Year Arm | Herceptin 2-Year Arm | Total |
|---|---|---|---|---|
| Mean | 49.2 ± 10.08 | 49.0 ± 10.06 | 49.2 ± 10.09 | 49.1 ± 10.08 |
| Sex: Female, Male(Participants) | Observation Arm | Herceptin 1-Year Arm | Herceptin 2-Year Arm | Total |
|---|---|---|---|---|
| Female | 1697 | 1702 | 1700 | 5099 |
| Male | 0 | 0 | 0 | 0 |
Showing the first 100 of 203 sites across 33 countries. Choose a country and city above to see the rest.
The record gives a start of Nov 2001, a primary completion of Mar 2005 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2017, 12 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trastuzumab